Want to see SLXN full AI Analyst Report?
Silexion Therapeutics (SLXN) Ratios
Silexion Therapeutics Ratios
SLXN's free cash flow for Q2 2026 was $-2.92M. For the 2026 fiscal year, SLXN's free cash flow was increased by $0.00 and operating cash flow was $-2.92M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.41 | 0.64 | 2.27 | 5.49 | 1.17 |
| Quick Ratio | 2.41 | 0.64 | 2.27 | 5.49 | 1.17 |
| Cash Ratio | 2.17 | 0.34 | 2.09 | 5.13 | 0.11 |
| Solvency Ratio | -2.58 | -2.40 | -0.28 | -0.19 | -1.48 |
| Operating Cash Flow Ratio | -3.92 | -2.38 | -2.06 | -2.07 | -4.04 |
| Short-Term Operating Cash Flow Coverage | -59.45 | -8.36 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 2.02M | $ -4.60M | $ -12.33M | $ -7.57M | $ -101.12K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 1.57 | 0.03 | 0.03 | 0.00 |
| Debt-to-Equity Ratio | 0.18 | -1.13 | -0.01 | -0.03 | 0.00 |
| Debt-to-Capital Ratio | 0.15 | 8.95 | -0.01 | -0.03 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.10 | -2.88 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.77 | -0.72 | -0.34 | -0.88 | 1.00 |
| Debt Service Coverage Ratio | -60.95 | -15.61 | -518.67 | -45.02 | 0.00 |
| Interest Coverage Ratio | 894.77 | -241.75 | -520.11 | -45.41 | 0.00 |
| Debt to Market Cap | 0.18 | 0.02 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 3.62 | 7.28 | 0.16 | 0.02 | 0.00 |
| Net Debt to EBITDA | 0.46 | -0.20 | 0.95 | 2.10 | 0.05 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.03% | 99.60% | 97.36% | 92.81% | 100.00% |
| EBT Per EBIT | -102.38% | 131.33% | 108.44% | 89.74% | 80.01% |
| Return on Assets (ROA) | -165.10% | -574.33% | -94.03% | -34.45% | -0.65% |
| Return on Equity (ROE) | -457.63% | 412.21% | 31.93% | 30.15% | -0.66% |
| Return on Capital Employed (ROCE) | 260.98% | 1904.70% | -152.97% | -49.98% | -0.82% |
| Return on Invested Capital (ROIC) | 250.74% | -2504.18% | -147.57% | -49.25% | -0.82% |
| Return on Tangible Assets | -165.10% | -574.33% | -94.03% | -34.45% | -0.65% |
| Earnings Yield | -466.65% | -8.74% | -1.68% | -0.07% | -0.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -81.38 | -13.46 | -4.05 | -0.20 | -0.09 |
| Free Cash Flow Per Share | -81.44 | -13.49 | -4.06 | -0.20 | -0.09 |
| Dividend Paid and CapEx Coverage Ratio | -1202.11 | -381.64 | -377.42 | -83.38 | -351809.00 |
| Capital Expenditure Coverage Ratio | -1202.11 | -381.64 | -377.42 | -83.38 | -351809.00 |
| Operating Cash Flow Coverage Ratio | -23.12 | -1.87 | -26.49 | -12.31 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -424.19% | -4.48% | -1.54% | -0.08% | -0.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.21 | -11.42 | -59.51 | -1369.70 | -5753.42 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.98 | -47.15 | -19.00 | -412.90 | 37.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.24 | -22.34 | -64.77 | -1304.77 | -3087.67 |
| Price-to-Operating Cash Flow Ratio | -0.24 | -22.40 | -64.94 | -1320.42 | -3087.67 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.28 | 0.00 | 7.77 | -20.20 |
| Enterprise Value Multiple | 0.25 | -11.62 | -62.49 | -1155.82 | -5755.03 |
| Enterprise Value | -2.97M | 191.39M | 289.69M | 4.40B | 4.35B |
| EV to EBITDA | 0.25 | -11.62 | -62.49 | -1155.82 | -5755.03 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.27 | -22.74 | -63.80 | -1302.40 | -3087.64 |
| EV to Operating Cash Flow | 0.27 | -22.80 | -63.96 | -1318.02 | -3087.65 |
| Tangible Book Value Per Share | 19.58 | -6.39 | -10.79 | -0.42 | 6.96 |
| Shareholders’ Equity Per Share | 19.58 | -6.39 | -13.85 | -0.64 | 6.96 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.01 | -0.01 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -89.60 | -26.36 | -4.42 | -0.19 | -0.05 |
| Tax Burden | 1.00 | 1.00 | 0.97 | 0.93 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.08 | 0.90 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.91 | 0.51 | 0.89 | 0.96 | 1.86 |
Currency in USD